Alexion Reports Third Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
Alexion Pharmaceuticals (ALXN) PT Lowered to $150 at Oppenheimer
October 24, 2019 9:25 AM EDTOppenheimer analyst Hartaj Singh lowered the price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $150.00 (from $165.00) while maintaining a Outperform rating.
The analyst commented, "Alexion (ALXN) reported 3Q19 sales/earnings and provided an investor update on 10/23. The company upgraded its financial guidance for... More
Alexion Pharma (ALXN) Tops Q3 EPS by 32c, Raises FY Guidance
October 23, 2019 6:35 AM EDTAlexion Pharma (NASDAQ: ALXN) reported Q3 EPS of $2.79, $0.32 better than the analyst estimate of $2.47. Revenue for the quarter came in at $1.26 billion versus the consensus estimate of $1.24 billion.
GUIDANCE:
Alexion Pharma sees FY2019 EPS of $10.25-$10.40, versus the consensus of... More
